Mild/Moderate 2019-nCoV Remdesivir RCT
Item
Click for External Resource*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
HyperlinkTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Title
Mild/Moderate 2019-nCoV Remdesivir RCT
Subject
Description
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay.
Given no specific antiviral therapy for 2019-nCoV infection and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate 2019-nCoV respiratory disease.
Given no specific antiviral therapy for 2019-nCoV infection and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate 2019-nCoV respiratory disease.
Creator
Date
2020-02-05
Was this resource helpful?